Virtus Biotech Clinical Trials ETF
11 hedge funds and large institutions have $8.61M invested in Virtus Biotech Clinical Trials ETF in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more capital invested
Capital invested by funds: $8.57M → $8.61M (+$36.9K)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.37M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$1.08M |
| 3 |
LPL Financial
San Diego,
California
|
+$192K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$75.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.44M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$53.8K |
| 3 |
BAAM
Baker Avenue Asset Management
San Francisco,
California
|
-$38.2K |
| 4 |
MPWT
MassMutual Private Wealth & Trust
Windsor,
Connecticut
|
-$8.14K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| $3.62M | -$3.44M | -100,000 | -50% |
|
|
2
Jane Street
New York
| $2.07M | +$1.37M | +39,905 | +232% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $1.13M | +$1.08M | +31,275 | New |
|
|
4
LPL Financial
San Diego,
California
| $897K | +$192K | +5,571 | +29% |
|
|
CS
5
Credit Suisse
Zurich,
Switzerland
| $511K | -$5.33K | -155 | -1% |
|
|
BAAM
6
Baker Avenue Asset Management
San Francisco,
California
| $254K | -$38.2K | -1,110 | -14% |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $80K | +$75.6K | +2,200 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $31K | +$21.5K | +624 | +267% |
|
|
AIG
9
American International Group
New York
| $9.05K | +$8.6K | +250 | New |
|
10
Morgan Stanley
New York
| $3K | -$3.44K | -100 | -59% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$53.8K | -1,566 | -100% |
|
|
MPWT
12
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$8.14K | -248 | Closed |
|
|
13
Creative Planning
Overland Park,
Kansas
| – | -$7K | -200 | Closed |
|
BBC Hedge Fund Activity: Q2 2015 in Review
11 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2015, worth a combined $8.61M — up 0.43% from $8.57M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBC positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Jane Street, adding an estimated $1.37M. The largest seller was Goldman Sachs, cutting an estimated $3.44M.
- 11 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2015, up from 10 in Q1 2015.
- Funds reported $8.61M of Virtus Biotech Clinical Trials ETF stock for Q2 2015, up 0.43% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2015 and 2 closed out, a net change of +1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2015 was Jane Street, an estimated $1.37M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2015 was Goldman Sachs, an estimated $3.44M sold.
Based on aggregated 13F filings for Q2 2015.